Fund moves
95 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 1, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 3, 2025 · Filed Nov 4, 2025
Merck's Chief Info&Digital Officer sold $720K of Merck shares. The filing references dividend reinvestment.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$720,040
Shares × reported transaction price
4 days after results of Oct 30, 2025, 92 days before results of Feb 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $82.49 on Nov 3, 2025, 12% above its 52-week low and 21% below its high, after a 3% rise over the previous 30 trading days
52-week range $73.47 (May 14, 2025) to $103.79 (Dec 9, 2024), 30% of the way up, from 250 adjusted closes. 30 trading days earlier: $80.40 on Sep 22, 2025. Describes the past only, not a forecast
RSI 38, 2% under its 200-day average, 2% under its 50-day average, 21% below the 52-week high, 20-day volatility 21% a year, against the S&P 500: −10 points over 1 month, −7 points over 3 months, −22 points over 6 months
From the adjusted closes up to Nov 3, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references dividend reinvestment
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Feb 12, 2025 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.
IN RE MERCK & CO., INC. SECURITIES LITIGATION, docket 2:25-cv-01208, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Winrevair on Oct 24, 2025, 10 days before this trade.
New use approved (efficacy supplement). Active ingredient: Sotatercept-Csrk. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +8.4% | +0.9% | +7.5% |
| 30 days | +18.2% | +1.2% | +17.0% |
| 90 days | +37.3% | +1.8% | +35.5% |
| 180 days | +34.0% | +6.0% | +28.1% |
| 365 days | +74.1% | +8.2% | +65.9% |
Past results only. Not a forecast.
Fund moves
95 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 1, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
7 tracked managers disclosed the same change for Q2 2025. From a 13F filed Nov 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
95 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 14, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.